Rett Syndrome Registry
RSR
Rett Syndrome Real World Data Observational Registry
1 other identifier
observational
3,000
1 country
18
Brief Summary
The Rett Syndrome Registry is a longitudinal observational study of individuals with MECP2 mutations and a diagnosis of Rett syndrome. Designed together with the IRSF Rett Syndrome Center of Excellence Network medical directors, this study collects data on the signs and symptoms of Rett syndrome as reported by the Rett syndrome experts and by the caregivers of individuals with Rett syndrome. This study will be used to develop consensus based guidelines for the care of your loved ones with Rett syndrome and to facilitate the development of better clinical trials and other aspects of the drug development path for Rett syndrome.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2022
Longer than P75 for all trials
18 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 5, 2022
CompletedFirst Posted
Study publicly available on registry
June 27, 2022
CompletedStudy Start
First participant enrolled
August 2, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2028
January 11, 2023
January 1, 2023
4.9 years
April 5, 2022
January 9, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Natural History
To longitudinally evaluate the natural history of patients with mutations on the MECP2 gene, estimating and defining their clinical spectrum (e.g. disease course and complications of disease).
5 years
Eligibility Criteria
The study population is males and females of all ages with a loss of function alteration of the MECP2 gene, most commonly resulting in Rett syndrome.
You may qualify if:
- Male or female with a pathologic loss of function alteration of MECP2
You may not qualify if:
- Male or female with a gain of function alteration of MECP2, including those with MEPC2 duplication or triplication
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- International Rett Syndrome Foundationlead
- Boston Children's Hospitalcollaborator
- Children's Health UTSWcollaborator
- Children's Hospital Coloradocollaborator
- Children's Hospital of Philadelphiacollaborator
- Gillette Children's Specialty Healthcarecollaborator
- Greenwood Genetic Centercollaborator
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.collaborator
- Montefiore Medical Centercollaborator
- Rush Universitycollaborator
- St. Louis Children's Hospitalcollaborator
- Baylor College of Medicinecollaborator
- University of Alabama at Birminghamcollaborator
- UCSF Benioff Children's Hospital Oaklandcollaborator
- Vanderbilt University Medical Centercollaborator
- Hive Networkscollaborator
Study Sites (18)
University of Alabama
Birmingham, Alabama, 35233, United States
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
UCSF Benioff Children's Hospital
Oakland, California, 94609, United States
Children's Hospital Colorado
Denver, Colorado, 80045, United States
Rush University Medical Center
Chicago, Illinois, 60612, United States
Kennedy Krieger Institute
Baltimore, Maryland, 21205, United States
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
Gillette Children's Specialty Healthcare
Saint Paul, Minnesota, 55101, United States
Washington University in St. Louis
St Louis, Missouri, 63110, United States
The Children's Hospital at Montefiore
The Bronx, New York, 10467, United States
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27517, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
Greenwood Genetic Center
Greenwood, South Carolina, 29646, United States
Vanderbilt Kennedy Center
Nashville, Tennessee, 37232, United States
Children's Health
Dallas, Texas, 75207, United States
Texas Children's Hospital
Houston, Texas, 77030, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 5 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 5, 2022
First Posted
June 27, 2022
Study Start
August 2, 2022
Primary Completion (Estimated)
July 1, 2027
Study Completion (Estimated)
July 1, 2028
Last Updated
January 11, 2023
Record last verified: 2023-01